Researchers and scientists at America’s biopharmaceutical companies and around the globe work every day to translate science into new treatments and cures to allow patients to live longer, healthier lives. This work is particularly important to people facing illnesses that have historically had limited treatment options, like cancer, lupus and multiple sclerosis (MS).
Fortunately for these patients in need, the pipeline of new, innovative medicines has never been more promising, and advances in recent decades have brought a number of therapies to people battling a disease or managing a chronic condition that have helped improved outcomes.
Today, researchers and scientists are currently developing more than 7,000 medicines worldwide. This includes more than 800 medicines in development for cancer and more than 300 medicines in the research pipeline for autoimmune diseases like lupus and MS.
For the research teams working every day to discover new medicines, the years they spend bringing therapies to patients require drawing on personal experiences to inspire and motivate them.
In a new video, Luciano Rossetti, M.D., head of global research and development at EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, explains the commitment and perseverance it takes for researchers and scientists to achieve breakthroughs in cancer medicines for patients. “Patients need to know that any new advancement in the treatments of disease is the fruit of 10-15 years of major efforts from extremely talented scientists and [researchers],” says Rosetti.
In his current role, Rossetti sees the dedication of EMD Serono’s research teams resulting in critical oncology medicine breakthroughs aimed at positive outcomes for people battling serious diseases. His personal experiences helping his father with diabetes and later his mother with metastatic breast cancer helped shape his passion for researching new treatments.
The work of researchers in translating complex science into treatments reflects the critical role the biopharmaceutical industry plays within the health care ecosystem.
To learn more about the scientists advancing breakthroughs in the lab, click here.
Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organizations scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.